[1]张司马康,刘鹏辉,许森,等.TACE联合消融及靶向免疫综合治疗原发性肝癌的回顾性研究[J].介入放射学杂志,2025,34(03):301-306.
　ZHANG Simakang,LIU Penghui,XU Sen,et al.TACE combined with ablation and targeted immunotherapy for hepatocellular carcinoma：a retrospective study[J].journal interventional radiology,2025,34(03):301-306.
点击复制

TACE联合消融及靶向免疫综合治疗原发性肝癌的回顾性研究()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
34
期数:
2025年03
页码:
301-306
栏目:
临床研究
出版日期:
2025-03-25

文章信息/Info

Title:
TACE combined with ablation and targeted immunotherapy for hepatocellular carcinoma：a retrospective study
作者:
张司马康; 刘鹏辉; 许森; 倪建明; 陈万海
Author(s):
ZHANG Simakang; LIU Penghui; XU Sen; NI Jianmin; CHEN Wanhai
Department of Interventional Radiology，Affiliated Central Hospital of Jiangnan University，Wuxi，Jiangsu Province 214000，China
关键词:
【关键词】原发性肝癌; 肝动脉化疗栓塞; 靶向治疗; 免疫治疗
文献标志码:
A
摘要:
【摘要】目的探讨经导管动脉化疗栓塞术（TACE）联合微波消融及靶向免疫综合治疗原发性肝细胞癌（HCC）的疗效分析。方法回顾性分析2016年8月至2023年8月江南大学附属中心医院收治的行TACE治疗的肝癌患者临床数据。根据标准入组的252例患者，按照治疗方法分为两组：TACE联合消融及靶向免疫四联（联合组）41例，单纯TACE（对照组）211例。对两组患者的总生存期（OS）和无进展生存期（PFS）进行统计分析。利用倾向性得分匹配，按1∶1进行配对后分析两种治疗方式的临床效果。据资料不同采用t检验、χ2检验、Kaplan-Meier曲线、对数秩检验、Cox回归分析或Cox比例风险模型分析进行统计学分析。结果多因素回归显示，肿瘤数目及最大直径、大血管侵犯、包膜、甲胎蛋白（AFP）、天冬氨酸转氨酶、BCLC分期、Child-Pugh肝功能分期是患者生存期的独立危险因素。影像学应答以及是否行联合治疗是生存期的保护因素。倾向性得分匹配实际匹配37对，配对后组间基线资料具有可比性。两组人群OS和FPS具有显著差异。TACE联合消融及靶向免疫综合治疗原发性肝癌可显著延长患者OS和PFS。结论TACE联合消融及靶向免疫综合治疗对比单纯TACE治疗是一种更有效的肝癌治疗方式，显著提升了生存期和无疾病进展生存期。

参考文献/References:

［1］Chang Y，Jeong SW，Young JJ，et al.Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma［J］.Int J Mol Sci，2020，21：8165.
［2］ Villanueva A.Hepatocellular Carcinoma［J］.N Engl J Med，2019，380：1450-1462.
［3］Lanza E，Donadon M，Poretti D，et al.Transarterial therapies for hepatocellular carcinoma［J］.Liver Cancer，2016，6：27-33.
［4］Han K，Kim JH.Transarterial chemoembolization in hepatocellular carcinoma treatment：Barcelona clinic liver cancer staging system［J］.World J Gastroenterol，2015，21：10327-10335.
［5］ Tsurusaki M，Murakami T.Surgical and locoregional therapy of HCC：TACE［J］.Liver Cancer，2015，4：165-175.
［6］Wang F，Gao S，Wu M，et al.The prognostic role of the AST/ALT ratio in hepatocellular carcinoma patients receiving thermal ablation combined with simultaneous TACE［J］.BMC Gastroenterol，2023，23：80.
［7］Liu C，Li T，He JT，et al.TACE combined with microwave ablation therapy vs.TACE alone for treatment of early-and intermediate-stage hepatocellular carcinomas larger than 5 cm：a meta-analysis［J］.Diagn Interv Radiol，2020，26：575-583.
［8］Yin X，Zhang L，Wang YH，et al.Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate （BCLC B） hepatocellular carcinoma［J］.BMC Cancer，2014，14：849.
［9］Kudo M，Ueshima K，Ikeda M，et al.Randomised，multicentre prospective trial of transarterial chemoembolisation （TACE） plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma：TACTICS trial［J］.Gut，2020，69：1492-1501.
［10］张玉晨，季敏，张梦辉，等.TACE联合TKI及PD-1抑制剂治疗初始不可切除肝细胞癌的疗效及安全性［J］.中华肝胆外科杂志，2023，29：412-417.
［11］Abdelaziz AO，Abdelhalim H，Elsharkawy A，et al.Liver stiffness measurement changes following hepatocellular carcinoma treatment with percutaneous microwave ablation or transarterial chemoembolization：a cohort study［J］.Eur J Gastroenterol Hepatol，2019，31：685-691.
［12］刘金，曹刚，张根山，等.卡瑞利珠单抗联合阿帕替尼治疗D-TACE后进展的中晚期肝癌的初步疗效及安全性分析［J］.中华医学杂志，2021，101：2304-2309.
［13］顾杰，许晨，周卫忠，等.TACE联合阿帕替尼对比单独TACE治疗中晚期原发性肝癌的倾向性匹配分析［J］.介入放射学杂志，2021，30：724-729.
［14］冯超凡，胡继红，张学贤，等.DEB-TACE联合MWA及阿帕替尼治疗巨块型肝癌的临床疗效［J］.介入放射学杂志，2022，31：254-258.
［15］Elshaarawy O，Gomaa A，Omar H，et al.Intermediate stage hepatocellular carcinoma：a summary review［J］.J Hepatocell Carcinoma，2019，6：105-117.

相似文献/References:

[1]陆骊工,胡宝山,李勇,等.中晚期原发性肝癌合并症的介入治疗研究[J].介入放射学杂志,2008,(07):514.
　LU Ligong,HU Baoshan,LI Yong,et al.Study of interventional therapy for complications in advanced primary hepatocellular carcinoma[J].journal interventional radiology,2008,(03):514.
[2]李晓光,金征宇,潘杰,等.肝动脉化疗或栓塞治疗胰腺神经内分泌肿瘤肝转移的疗效分析[J].介入放射学杂志,2010,(06):442.
　LI Xiaoguang,JIN Zhengyu,PAN Jie,et al.Hepatic transarterial chemoperfusion and chemoembolization for the treatment of liver metastases from pancreatic neuroendocrine tumors：a therapeutic analysis[J].journal interventional radiology,2010,(03):442.
[3]杨学东,张志良,马戈,等.肝动脉化疗栓塞与三维立体定向放疗配合治疗原发性肝癌[J].介入放射学杂志,2009,(03):193.
　YANG Xuedong,ZHANG Zhiliang,MA Ge,et al.Hepatic arterial chemoembolization combined with３D conformal radiotherapy for primary hepatic carcinoma[J].journal interventional radiology,2009,(03):193.
[4]郑加生,李建军,崔雄伟,等.肝动脉化疗栓塞联合CT引导下射频消融术治疗肝癌的疗效分析[J].介入放射学杂志,2009,(05):324.
　ZHENG Jia-sheng,LI Jian-jun,CUI Xiong-wei,et al.Therapeutic combination of hepatic arterial chemoembolization with CT鄄guided radiofrequency ablation for hepatocellular carcinoma：an analysis of curative effect[J].journal interventional radiology,2009,(03):324.
[5]刘德鑫,李华东,李新丰,等.肝动脉栓塞化疗联合射频及无水乙醇注射治疗中晚期肝癌的评价[J].介入放射学杂志,2009,(05):389.
　LIU De-xin,LI Hua-dong,LI Xin-feng,et al.Evaluation of TACE combined with RFA and PEI in treating advanced hepatic carcinoma[J].journal interventional radiology,2009,(03):389.
[6]周怡婷,曹建民,许健,等.氩氦刀联合栓塞化疗治疗中晚期肝癌的临床研究[J].介入放射学杂志,2009,(10):733.
　ZHOU Yiting,CAO Jianming,XU Jian,et al.Cryotherapy combined with chemoembolization for the treatment of advanced hepatic carcinoma ：a clinical study[J].journal interventional radiology,2009,(03):733.
[7]纪昌学,陈宪,涂蓉,等.经肝动脉化疗栓塞对高危因素肝癌的疗效观察[J].介入放射学杂志,2007,(06):378.
　JI Chang-xue,CHEN Xian,TU Rong,et al.Therapeutic efficacy of transcatheter arterial chemoembolization for liver cancer with high-risk factors[J].journal interventional radiology,2007,(03):378.
[8]徐中琪,刘晟,许贇,等.完全性胸腹腔内脏反位合并原发性肝癌行经皮微波消融治疗4例[J].介入放射学杂志,2016,(06):546.
　XU Zhong-qi,LIU Sheng,XU Yun,et al.Percutaneous microwave ablation for primary hepatocellular carcinoma in patients with thoracic and abdominal situs inversus totalis: report of 4 cases [J].journal interventional radiology,2016,(03):546.
[9]陆阳,汤蕊嘉,谢璇丞,等.TACE联合阿帕替尼治疗中晚期肝细胞癌无进展生存时间的影响因素分析 [J].介入放射学杂志,2020,29(03):246.
　LU Yang,TANG Ruijia,XIE Xuancheng,et al.Analysis of influencing factors of progression-free survival in patients with advanced HCC treated with TACE combined with apatinib[J].journal interventional radiology,2020,29(03):246.
[10]蒋健强,李晓娟,李拥军,等.白蛋白-胆红素评分在预测TACE治疗巨块型肝细胞癌后肝功能衰竭中的应用[J].介入放射学杂志,2023,32(01):55.
　JIANG Jianqiang,LI Xiaojuan,LI Yongjun,et al.The application of albumin-bilirubin score in predicting liver failure after transarterial chemoembolization for massive hepatocellular carcinoma [J].journal interventional radiology,2023,32(03):55.

备注/Memo

备注/Memo:
（收稿日期：2024-03-11）
（本文编辑：茹实）
更新日期/Last Update: 2025-03-25